Biotherapeutics: Positive Uveitis Study Results From XOMA
June 21, 2010 (FinancialWire) — XOMA Ltd. (NASDAQ: XOMA) has released positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal …